Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

Eur J Health Econ. 2014 Apr;15(3):223-8. doi: 10.1007/s10198-013-0538-4. Epub 2013 Nov 23.
No abstract available

Publication types

  • Editorial
  • Review

MeSH terms

  • Biosimilar Pharmaceuticals / economics*
  • Cost Control
  • Economic Competition / economics*
  • Europe
  • Fees, Pharmaceutical*
  • Humans

Substances

  • Biosimilar Pharmaceuticals